Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd

Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS) will announce its fourth quarter and full year 2022 financial results before the Nasdaq Global Market opens on March 22, 2023. CEO Jill C. Milne, Ph.D., will lead a conference call and webcast at 8:30am ET to discuss these results and provide updates on corporate developments. The company's lead program, STAR-0215, is in clinical development for hereditary angioedema. Interested parties can access the webcast through the Astria website. The announcement aims to inform investors and stakeholders of the company’s performance and future outlook.

Positive

• Upcoming financial results announcement on March 22, 2023.
• CEO will discuss corporate developments during the webcast.

Negative

• None.

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss fourth quarter and full year 2022 financial results.

Webcast Information:
Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com or with the following link: https://lifescievents.com/event/astria-therapeutics-event/.

Please connect to the webcast several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be required. The webcast will be archived for 90 days.

About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005098/en/

Investor relations:

Andrea Matthews

investors@astriatx.com

Media:

Elizabeth Higgins

media@astriatx.com

Source: Astria Therapeutics, Inc.

FAQ

When will Astria Therapeutics report its Q4 and full year 2022 results?

Astria Therapeutics will report its results on March 22, 2023.

What is the significance of STAR-0215 in Astria's development pipeline?

STAR-0215 is a monoclonal antibody in clinical development for hereditary angioedema.

What time is the investor conference call for Astria Therapeutics?

The conference call will be held at 8:30am ET on March 22, 2023.